Recent Quotes (30 days)

You have no recent quotes
chg | %

Aptose Biosciences Inc  

(Public, TSE:APS)   Watch this stock  
Find more results for TSE:LOR
1.86
-0.04 (-2.11%)
Delayed:   12:56PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.84 - 1.95
52 week 1.05 - 4.02
Open 1.95
Vol / Avg. 4,995.00/42,228.00
Mkt cap 44.55M
P/E     -
Div/yield     -
EPS -1.00
Shares 23.95M
Beta 2.67
Inst. own     -
Nov 13, 2017
Q3 2017 Aptose Biosciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 10, 2017
Aptose Biosciences Inc at Canaccord Genuity Growth Conference
Aug 8, 2017
Q2 2017 Aptose Biosciences Inc Earnings Call - Webcast
Aug 8, 2017
Q2 2017 Aptose Biosciences Inc Earnings Release
Jun 21, 2017
Aptose Biosciences Inc Annual Shareholders Meeting (Estimated)
Jun 6, 2017
Aptose Biosciences Inc Annual Shareholders Meeting
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -95.02% -113.38%
Return on average equity -109.63% -129.66%
Employees 21 -
CDP Score - -

Address

5955 Airport Rd Suite 228
MISSISSAUGA, ON L4V 1R9
Canada
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links

Description

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Denis R. Burger Ph.D. Independent Director
Age: 70
Erich M. Platzer M.D., Ph.D. Independent Director
Bradley Thompson Independent Director
Mark D. Vincent M.D. Independent Director
Warren Whitehead Independent Director